vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.
VIRTUS INVESTMENT PARTNERS, INC. is the larger business by last-quarter revenue ($199.5M vs $185.2M, roughly 1.1× AMICUS THERAPEUTICS, INC.). VIRTUS INVESTMENT PARTNERS, INC. runs the higher net margin — 3.6% vs 0.9%, a 2.6% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs -4.1%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs -5.7%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
VIRTUS INVESTMENT PARTNERS, INC.VRTSEarnings & Financial Report
Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.
FOLD vs VRTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $199.5M |
| Net Profit | $1.7M | $7.1M |
| Gross Margin | 85.7% | — |
| Operating Margin | 8.6% | 7.7% |
| Net Margin | 0.9% | 3.6% |
| Revenue YoY | 23.7% | -4.1% |
| Net Profit YoY | -88.5% | -78.1% |
| EPS (diluted) | $0.00 | $1.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $199.5M | ||
| Q4 25 | $185.2M | $208.0M | ||
| Q3 25 | $169.1M | $216.4M | ||
| Q2 25 | $154.7M | $210.5M | ||
| Q1 25 | $125.2M | $217.9M | ||
| Q4 24 | $149.7M | $233.5M | ||
| Q3 24 | $141.5M | $227.0M | ||
| Q2 24 | $126.7M | $224.4M |
| Q1 26 | — | $7.1M | ||
| Q4 25 | $1.7M | $33.9M | ||
| Q3 25 | $17.3M | $31.3M | ||
| Q2 25 | $-24.4M | $42.7M | ||
| Q1 25 | $-21.7M | $28.1M | ||
| Q4 24 | $14.7M | $39.5M | ||
| Q3 24 | $-6.7M | $49.1M | ||
| Q2 24 | $-15.7M | $26.0M |
| Q1 26 | — | — | ||
| Q4 25 | 85.7% | — | ||
| Q3 25 | 88.5% | — | ||
| Q2 25 | 90.2% | — | ||
| Q1 25 | 90.7% | — | ||
| Q4 24 | 90.1% | — | ||
| Q3 24 | 90.6% | — | ||
| Q2 24 | 91.1% | — |
| Q1 26 | — | 7.7% | ||
| Q4 25 | 8.6% | 19.1% | ||
| Q3 25 | 20.3% | 21.7% | ||
| Q2 25 | -6.1% | 21.5% | ||
| Q1 25 | -6.3% | 16.8% | ||
| Q4 24 | 10.7% | 21.7% | ||
| Q3 24 | 15.3% | 24.3% | ||
| Q2 24 | 11.8% | 19.7% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | 0.9% | 16.3% | ||
| Q3 25 | 10.2% | 14.5% | ||
| Q2 25 | -15.8% | 20.3% | ||
| Q1 25 | -17.3% | 12.9% | ||
| Q4 24 | 9.8% | 16.9% | ||
| Q3 24 | -4.8% | 21.6% | ||
| Q2 24 | -12.4% | 11.6% |
| Q1 26 | — | $1.05 | ||
| Q4 25 | $0.00 | $5.15 | ||
| Q3 25 | $0.06 | $4.65 | ||
| Q2 25 | $-0.08 | $6.12 | ||
| Q1 25 | $-0.07 | $4.05 | ||
| Q4 24 | $0.05 | $4.65 | ||
| Q3 24 | $-0.02 | $5.71 | ||
| Q2 24 | $-0.05 | $2.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $136.6M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $93.6B |
| Total Assets | $949.9M | — |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $136.6M | ||
| Q4 25 | $293.5M | — | ||
| Q3 25 | $263.8M | — | ||
| Q2 25 | $231.0M | — | ||
| Q1 25 | $250.6M | — | ||
| Q4 24 | $249.9M | — | ||
| Q3 24 | $249.8M | — | ||
| Q2 24 | $260.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | $392.7M | $390.0M | ||
| Q3 25 | $392.0M | $390.6M | ||
| Q2 25 | $391.3M | $231.3M | ||
| Q1 25 | $390.7M | $231.7M | ||
| Q4 24 | $390.1M | $232.1M | ||
| Q3 24 | $389.5M | $237.5M | ||
| Q2 24 | $388.9M | $247.6M |
| Q1 26 | — | $93.6B | ||
| Q4 25 | $274.2M | $934.0M | ||
| Q3 25 | $230.4M | $918.7M | ||
| Q2 25 | $204.3M | $896.4M | ||
| Q1 25 | $193.6M | $893.7M | ||
| Q4 24 | $194.0M | $897.5M | ||
| Q3 24 | $178.8M | $889.0M | ||
| Q2 24 | $132.5M | $868.7M |
| Q1 26 | — | — | ||
| Q4 25 | $949.9M | $4.3B | ||
| Q3 25 | $868.8M | $3.9B | ||
| Q2 25 | $815.3M | $3.7B | ||
| Q1 25 | $789.8M | $3.7B | ||
| Q4 24 | $785.0M | $4.0B | ||
| Q3 24 | $786.6M | $3.6B | ||
| Q2 24 | $749.5M | $3.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 0.42× | ||
| Q3 25 | 1.70× | 0.43× | ||
| Q2 25 | 1.92× | 0.26× | ||
| Q1 25 | 2.02× | 0.26× | ||
| Q4 24 | 2.01× | 0.26× | ||
| Q3 24 | 2.18× | 0.27× | ||
| Q2 24 | 2.93× | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | — |
| Free Cash FlowOCF − Capex | $16.0M | — |
| FCF MarginFCF / Revenue | 8.6% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 9.62× | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $16.3M | $-67.2M | ||
| Q3 25 | $35.7M | $108.3M | ||
| Q2 25 | $-26.5M | $75.8M | ||
| Q1 25 | $7.8M | $-3.8M | ||
| Q4 24 | $-3.9M | $1.8M | ||
| Q3 24 | $-23.0M | $69.1M | ||
| Q2 24 | $22.7M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $16.0M | $-74.1M | ||
| Q3 25 | $35.3M | $106.9M | ||
| Q2 25 | $-28.9M | $74.2M | ||
| Q1 25 | $7.5M | $-6.8M | ||
| Q4 24 | $-4.2M | $-3.8M | ||
| Q3 24 | $-23.3M | $68.7M | ||
| Q2 24 | $21.6M | $68.6M |
| Q1 26 | — | — | ||
| Q4 25 | 8.6% | -35.6% | ||
| Q3 25 | 20.9% | 49.4% | ||
| Q2 25 | -18.7% | 35.2% | ||
| Q1 25 | 6.0% | -3.1% | ||
| Q4 24 | -2.8% | -1.6% | ||
| Q3 24 | -16.5% | 30.3% | ||
| Q2 24 | 17.0% | 30.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 3.3% | ||
| Q3 25 | 0.2% | 0.7% | ||
| Q2 25 | 1.6% | 0.7% | ||
| Q1 25 | 0.2% | 1.4% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.3% | 0.2% | ||
| Q2 24 | 0.9% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 9.62× | -1.99× | ||
| Q3 25 | 2.06× | 3.45× | ||
| Q2 25 | — | 1.77× | ||
| Q1 25 | — | -0.13× | ||
| Q4 24 | -0.27× | 0.04× | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 2.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
VRTS
| Investment management fees | $169.1M | 85% |
| Administration and shareholder service fees | $17.3M | 9% |
| Distribution and service fees | $11.6M | 6% |
